KBC Group
AMRX icon

KBC Group’s Amneal Pharmaceuticals AMRX Stock Holding History

KBC Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80K Buy
+6,417
New +$86.2K ﹤0.01% 1453
2019
Q4 		– Sell
-55,579
Closed -$161K – 1493
2019
Q3 		$161K Buy
+55,579
New +$194K ﹤0.01% 1283

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

KBC Group's AMRX Position: Q1 2026 in Review

KBC Group opened a new position in Amneal Pharmaceuticals (AMRX) in Q1 2026: 6,417 shares worth $80K. The stake represents ﹤0.01% of the portfolio and ranks #1453 among its holdings. This is a return to the name: KBC Group previously reported a position in AMRX as recently as Q3 2019.

KBC Group first reported a position in AMRX in Q3 2019 and has held it in 2 quarters since. The position peaked at $161K in Q3 2019. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • KBC Group held 6,417 shares of Amneal Pharmaceuticals worth $80K as of Q1 2026.
  • Amneal Pharmaceuticals was a new KBC Group position in Q1 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1453 holding.
  • KBC Group first reported a position in Amneal Pharmaceuticals in Q3 2019 and has held it in 2 quarters since.
  • KBC Group's Amneal Pharmaceuticals position peaked at $161K in Q3 2019.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.